valuation for multiple indications - find some mod
Post# of 148172
Are there a list of models we can build on that will help us create a valuation for Leonlimab. At one extreme, we are only worth the value of the first indication that gets approval. If we were on shark tank, none of the investors will consider paying for un approved indications, but they would also insist on owning future indications.
If investors can have it both ways now that Nader is gone. I think this is the biggest question for the new management. What is Leronlimabs valuation?
I suggest we build on a list of model drugs that each have dozens of indications. We present the list to management by maintaining it on this board. The resources of this board may be greater than the time and effort management can spend on this topic.
Who else thinks multiple indications valuation is topic number 1 after the Getting Approval topic?